Neoadjuvant systemic therapy for urological malignancies.

摘要: Neoadjuvant cisplatin-based combined chemotherapy is an established standard for muscle-invasive bladder cancer and pathological complete remission excellent intermediate surrogate endpoint survival. Phase III trials are ongoing to elucidate the role of neoadjuvant androgen deprivation docetaxel-based localized high-risk prostate cancer. therapy with biological agents targeting angiogenesis preceding cytoreductive nephrectomy metastatic renal cell carcinoma a novel approach, although randomized validating this paradigm attempting establish timing necessity nephrectomy. provide window opportunity evaluate screen activity by using brief surgery rationale further develop most promising in larger trials. The approach followed acceptable feasible wide array urological cancers provides evaluating activity, mechanism action resistance new treatments. Urological initially characterized presentation vast majority cases, coupled substantial risk distant relapses following surgical resection. Therefore, may expedite development systemic improve outcomes.